Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.

Objectives: Several studies have reported the role of immune-related adverse events as a predictor of clinical benefit, but few have properly described these findings in advanced or metastatic non-small cell lung cancer treated with pembrolizumab. This study aimed to evaluate the association between immune-related adverse events development and clinical outcomes in the aforementioned group of patients.

Methods: We conducted a retrospective study in patients with advanced or metastatic non-small cell lung cancer treated with pembrolizumab.